CA3072673A1 - Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells - Google Patents
Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells Download PDFInfo
- Publication number
- CA3072673A1 CA3072673A1 CA3072673A CA3072673A CA3072673A1 CA 3072673 A1 CA3072673 A1 CA 3072673A1 CA 3072673 A CA3072673 A CA 3072673A CA 3072673 A CA3072673 A CA 3072673A CA 3072673 A1 CA3072673 A1 CA 3072673A1
- Authority
- CA
- Canada
- Prior art keywords
- eye
- condition
- cells
- disease
- ophthalmic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/675,171 | 2017-08-11 | ||
| US15/675,171 US20180000816A1 (en) | 2015-02-06 | 2017-08-11 | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| US201762579793P | 2017-10-31 | 2017-10-31 | |
| US62/579,793 | 2017-10-31 | ||
| PCT/US2018/046553 WO2019033119A1 (en) | 2017-08-11 | 2018-08-13 | TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3072673A1 true CA3072673A1 (en) | 2019-02-14 |
Family
ID=63254539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3072673A Pending CA3072673A1 (en) | 2017-08-11 | 2018-08-13 | Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP3441069B1 (https=) |
| JP (2) | JP7278257B2 (https=) |
| CN (1) | CN111372598A (https=) |
| AU (2) | AU2018314280B2 (https=) |
| CA (1) | CA3072673A1 (https=) |
| MX (2) | MX2020001644A (https=) |
| WO (1) | WO2019033119A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200354336A9 (en) | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| JP7080346B2 (ja) | 2018-04-30 | 2022-06-03 | ユニティ バイオテクノロジー インコーポレイテッド | 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホノアミダート |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| KR20240014102A (ko) | 2018-06-29 | 2024-01-31 | 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 | 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법 |
| CA3109432A1 (en) * | 2018-08-20 | 2020-02-27 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| JP2022548071A (ja) * | 2019-09-13 | 2022-11-16 | アメリカ合衆国 | 網膜変性を治療するための新薬の開発につながる標的 |
| CN113025633B (zh) | 2019-12-09 | 2024-08-27 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
| US20230078120A1 (en) * | 2020-05-04 | 2023-03-16 | Ascentage Pharma (Suzhou) Co.,Ltd. | Methods for Treating Coronavirus Infections |
| JP2024501033A (ja) * | 2020-12-28 | 2024-01-10 | エムディー ヘルスケア インコーポレイテッド | ミクロコッカス・ルテウス由来細胞外小胞を含む眼疾患の予防または治療用組成物 |
| CN117222414A (zh) | 2021-03-01 | 2023-12-12 | 脱落性治疗公司 | 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法 |
| JP2024516367A (ja) * | 2021-04-13 | 2024-04-15 | ユニティ バイオテクノロジー インコーポレイテッド | 網膜血管症を治療する方法 |
| KR102625248B1 (ko) * | 2021-05-04 | 2024-01-16 | 주식회사 퓨전바이오텍 | 이미다졸린 유도체 화합물을 유효성분으로 포함하는 황반 변성 치료용 약학적 조성물 |
| WO2024051741A1 (zh) * | 2022-09-06 | 2024-03-14 | 西藏海思科制药有限公司 | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 |
| DE112024002866T5 (de) * | 2023-07-06 | 2026-04-23 | Jichi Medical University | Konzentrationsregulator für In-vivo-Substanzen oder Medikamente in einem halbgeschlossenen In-vivo-System |
| CN119925379B (zh) * | 2025-03-05 | 2025-09-05 | 中南大学湘雅医院 | Bcl3抑制剂在制备治疗青光眼的药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| BR0208856B1 (pt) | 2001-04-11 | 2013-02-05 | processo para o tratamento de superfÍcie de uma junta com rosca e junta com rosca para tubos de aÇo. | |
| US9804295B2 (en) | 2005-05-05 | 2017-10-31 | Novartis Ag | Ophthalmic devices for sustained delivery of active compounds |
| WO2009094466A2 (en) | 2008-01-22 | 2009-07-30 | University Of Florida Research Foundation, Inc. | Contact lenses for extended release of bioactive agents containing diffusion attenuators |
| US8353856B2 (en) | 2008-11-05 | 2013-01-15 | Abbott Medical Optics Inc. | Glaucoma drainage shunts and methods of use |
| SG192126A1 (en) | 2011-01-25 | 2013-09-30 | Univ Michigan | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
| EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| KR102318204B1 (ko) | 2013-01-16 | 2021-10-26 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 |
| CN105377289A (zh) * | 2013-04-21 | 2016-03-02 | 耶达研究及发展有限公司 | 用于下调Bcl-xL和/或Bcl-w的活性和/或量的试剂 |
| US20150038140A1 (en) | 2013-07-31 | 2015-02-05 | Qualcomm Incorporated | Predictive mobility in cellular networks |
| WO2015017536A1 (en) | 2013-07-31 | 2015-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Method and system for evaluating progression of age-related macular degeneration |
| AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| CA2981753A1 (en) * | 2015-02-06 | 2016-08-11 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditions |
| WO2017008060A1 (en) * | 2015-07-08 | 2017-01-12 | Unity Biotechnology, Inc. | Compositions and methods for treating senescence-associated diseases and disorders |
| US11111259B2 (en) * | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
-
2018
- 2018-08-13 EP EP18188799.3A patent/EP3441069B1/en active Active
- 2018-08-13 CA CA3072673A patent/CA3072673A1/en active Pending
- 2018-08-13 AU AU2018314280A patent/AU2018314280B2/en active Active
- 2018-08-13 EP EP23166363.4A patent/EP4234025A3/en active Pending
- 2018-08-13 JP JP2020507573A patent/JP7278257B2/ja active Active
- 2018-08-13 MX MX2020001644A patent/MX2020001644A/es unknown
- 2018-08-13 WO PCT/US2018/046553 patent/WO2019033119A1/en not_active Ceased
- 2018-08-13 CN CN201880063962.8A patent/CN111372598A/zh active Pending
-
2020
- 2020-02-10 MX MX2025004366A patent/MX2025004366A/es unknown
-
2023
- 2023-05-08 JP JP2023076763A patent/JP2023100864A/ja active Pending
- 2023-10-16 AU AU2023251388A patent/AU2023251388B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025004366A (es) | 2025-05-02 |
| EP3441069A1 (en) | 2019-02-13 |
| JP2023100864A (ja) | 2023-07-19 |
| MX2020001644A (es) | 2020-07-13 |
| WO2019033119A1 (en) | 2019-02-14 |
| AU2018314280B2 (en) | 2023-07-20 |
| AU2023251388A1 (en) | 2023-11-02 |
| CN111372598A (zh) | 2020-07-03 |
| AU2018314280A1 (en) | 2020-02-27 |
| EP4234025A3 (en) | 2024-04-24 |
| RU2020109987A (ru) | 2021-09-13 |
| JP2020530470A (ja) | 2020-10-22 |
| EP3441069B1 (en) | 2023-04-05 |
| JP7278257B2 (ja) | 2023-05-19 |
| EP4234025A2 (en) | 2023-08-30 |
| AU2023251388B2 (en) | 2024-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023251388B2 (en) | Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells | |
| US11865123B2 (en) | Methods of inhibiting pathological angiogenesis | |
| Scuderi et al. | Pigment dispersion syndrome and pigmentary glaucoma: a review and update | |
| De Keyser et al. | Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients | |
| Davids et al. | Ab interno canaloplasty (ABiC)—12-month results of a new minimally invasive glaucoma surgery (MIGS) | |
| Park et al. | Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery: a randomized controlled trial | |
| Grzybowski et al. | The role of steroids and NSAIDs in prevention and treatment of postsurgical cystoid macular edema | |
| JP2023509336A (ja) | 過剰血管新生に関連する眼疾患を治療する化合物 | |
| TW201440774A (zh) | 眼底疾患治療劑 | |
| KR20190134588A (ko) | 다중 키나아제 억제제 및 안구 섬유증에의 사용 | |
| Komizo et al. | Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma | |
| Wood et al. | Rare corneal complication following selective laser trabeculoplasty | |
| WO2020009248A1 (ja) | 眼組織の線維化抑制用組成物 | |
| Galloway et al. | The Ageing Eye | |
| RU2815482C2 (ru) | Лечение глазных болезней типа дегенерации желтого пятна, глаукомы и диабетической ретинопатии с помощью лекарственных средств, устраняющих стареющие клетки | |
| HK40032714A (en) | Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells | |
| Fu et al. | Cystoid macular edema | |
| ALBÉ et al. | Ocular diseases of importance to the refractive surgeon | |
| Narayanaswamy et al. | Randomized, controlled trial of a sustained delivery formulation of 5-fluorouracil for the treatment of failing blebs | |
| Vallabh et al. | Pathology of Glaucoma | |
| Garg et al. | Ophthalmologic Disease in Systemic Lupus Erythematosus and Antiphospholipid Syndrome | |
| Dikmetas et al. | Glaucoma and ocular surface | |
| Elwakeel et al. | Results of intracameral dexamethasone injection versus intracameral triamcinolone acetonide injection at the end of phacoemulsification surgery | |
| Wu et al. | Ophthalmic Complications of the Rheumatic Diseases and Anti-Rheumatic Drugs (in Elderly) | |
| Jeganathan et al. | Challenges in the management of glaucoma in a patient with severe ocular surface disease: a case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230811 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240722 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240722 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240722 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240830 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241230 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250211 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250717 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250717 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260202 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260204 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260204 |